SETTING: The Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes (the GHESKIO AIDS and TB Center) in Port-au-Prince, Haiti. OBJECTIVE: To measure the effectiveness of the standard TB retreatment regimen (2HRZES/1HRZE/5HRE) in human immunodeficiency virus (HIV) infected adults. DESIGN: Cohort study. RESULTS: Of 1318 HIV-infected patients with access to antiretroviral therapy following World Health Organization guidelines, 56 were diagnosed with recurrent pulmonary TB and retreated with the standard retreatment regimen: 10 patients (18%) died during retreatment, 3 (5%) defaulted, and 2 (4%) failed treatment. Forty-one patients (73%) achieved retreatment 'success' (cure, treatment completed). Of these, 8 (20%) died during follow-up, 5 (12%) were lost, and 5 (12%) had a second recurrence of TB. Only 26 (46%) of the 56 patients remained alive, in care, and TB-free after a median of 36 months of follow-up. CONCLUSION: HIV-infected patients treated for recurrent TB with the standard retreatment regimen have high mortality and poor long-term outcomes.
SETTING: The Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes (the GHESKIO AIDS and TB Center) in Port-au-Prince, Haiti. OBJECTIVE: To measure the effectiveness of the standard TB retreatment regimen (2HRZES/1HRZE/5HRE) in human immunodeficiency virus (HIV) infected adults. DESIGN: Cohort study. RESULTS: Of 1318 HIV-infectedpatients with access to antiretroviral therapy following World Health Organization guidelines, 56 were diagnosed with recurrent pulmonary TB and retreated with the standard retreatment regimen: 10 patients (18%) died during retreatment, 3 (5%) defaulted, and 2 (4%) failed treatment. Forty-one patients (73%) achieved retreatment 'success' (cure, treatment completed). Of these, 8 (20%) died during follow-up, 5 (12%) were lost, and 5 (12%) had a second recurrence of TB. Only 26 (46%) of the 56 patients remained alive, in care, and TB-free after a median of 36 months of follow-up. CONCLUSION:HIV-infectedpatients treated for recurrent TB with the standard retreatment regimen have high mortality and poor long-term outcomes.
Authors: Patrice Severe; Paul Leger; Macarthur Charles; Francine Noel; Gerry Bonhomme; Gyrlande Bois; Erik George; Stefan Kenel-Pierre; Peter F Wright; Roy Gulick; Warren D Johnson; Jean William Pape; Daniel W Fitzgerald Journal: N Engl J Med Date: 2005-12-01 Impact factor: 91.245
Authors: Paul Leger; Macarthur Charles; Patrice Severe; Cynthia Riviere; Jean William Pape; Daniel W Fitzgerald Journal: N Engl J Med Date: 2009-08-20 Impact factor: 91.245
Authors: Wafaie W Fawzi; Gernard I Msamanga; Donna Spiegelman; Ruilan Wei; Saidi Kapiga; Eduardo Villamor; Davis Mwakagile; Ferdinand Mugusi; Ellen Hertzmark; Max Essex; David J Hunter Journal: N Engl J Med Date: 2004-07-01 Impact factor: 91.245
Authors: Y S Schreiber; A F Herrera; D Wilson; K Wallengren; R Draper; J Muller; H Dawood; S Doucette; D W Cameron; G G Alvarez Journal: Int J Tuberc Lung Dis Date: 2009-10 Impact factor: 2.373
Authors: Edward C Jones-López; Irene Ayakaka; Jonathan Levin; Nancy Reilly; Francis Mumbowa; Scott Dryden-Peterson; Grace Nyakoojo; Kevin Fennelly; Beth Temple; Susan Nakubulwa; Moses L Joloba; Alphonse Okwera; Kathleen D Eisenach; Ruth McNerney; Alison M Elliott; Jerrold J Ellner; Peter G Smith; Roy D Mugerwa Journal: PLoS Med Date: 2011-03-15 Impact factor: 11.069
Authors: L K Reif; V Rivera; R Bertrand; V Rouzier; E Kutscher; K Walsh; B Charles; J W Pape; D W Fitzgerald; S P Koenig; M L McNairy Journal: Public Health Action Date: 2018-09-21
Authors: Danielle B Cohen; Geriant Davies; Wakisa Malwafu; Helen Mangochi; Elizabeth Joekes; Simon Greenwood; Liz Corbett; S Bertel Squire Journal: PLoS One Date: 2019-05-06 Impact factor: 3.240